Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
|Articles|January 27, 2015
- Head and Neck Cancers (Issue 3)
- Volume 3
- Issue 1
The Challenges of Treating Follicular Cell-Derived Thyroid Carcinoma
Author(s)Keith C. Bible, MD, PhD
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the challenges associated with treating patients with follicular cell-derived thyroid carcinoma.
Advertisement
Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the challenges associated with treating patients with follicular cell-derived thyroid carcinoma.
Articles in this issue
over 11 years ago
Perspectives From the Clinic on AE Management in Thyroid Cancerover 11 years ago
Urging Families With Thyroid Cancer to Seek Genetic Testingalmost 12 years ago
Prognosis in Thyroid Cancer as Diverse as the Diseasealmost 12 years ago
The Diagnosis of Thyroid Canceralmost 12 years ago
National Surge in Thyroid Cancer Under Scrutinyalmost 12 years ago
Epidemic in Sex-Related Oral Cancer Highlights Need for Guidelinesalmost 12 years ago
Body Composition and Targeted Therapies in Thyroid CancerAdvertisement
Related to this article
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5